Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL-204 open-label phase 2 study of INCB050465 in relapsed or refractory marginal zone lymphoma
MOH_2018-02-04_000783Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of parsaclisib in marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by Incyte. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
parsaclisib
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on MOH_2018-02-04_000783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-04_000783.